Immuno & Gene Therapy Committee

Aims & Scope

The Immuno & Gene Therapy Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the cell and gene therapy category.
  • Review the status of the immuno & gene therapy field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing immunotherapy and gene therapy.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.

Selected Publications

Emerging frontiers in immuno-and gene therapy for cancer (Cytotherapy. 2022 In press)

Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience (Cytotherapy. 2022 Jan;24(1):16-18)

ISCT survey on hospital practices to support external manufactured investigational cell-gene therapy products (Cytotherapy. 2022 Jan;24(1):27-31)

Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies (Cytotherapy. 2020 May;22(9):474-481)

The Immuno-Gene Therapy Scientific Committee of the International Society for Cell & Gene Therapy (ISCT) sponsored a 2019 special edition in ISCT's flagship journal, Cytotherapy, with the goal of disseminating information about best-practice testing for a variety of cell types. (Cytotherapy. 2019 Mar;21(3))

Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen specific T cells (Cytotherapy. 2019 Mar;21(3):278-288)

Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency (Cytotherapy. 2019 Mar;21(3):289-306)

Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process (Cytotherapy. 2019 Mar;21(3):307-314)

Characterization of human natural killer cells for therapeutic use (Cytotherapy. 2019 Mar;21(3):315-326)

Manufacturing chimeric antigen receptor T cells: issues and challenges (Cytotherapy. 2019 Mar;21(3):327-340)

T-cell receptor gene-modified cells: past promises, present methodologies and future challenges (Cytotherapy. 2019 Mar;21(3):341-357)

Chemistry, manufacturing and controls for gene-modified hematopoietic stem cells (Cytotherapy. 2019 Mar;21(3):358-366)

Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapies (Cytotherapy. 2019 Mar;21(3):367-375)

The Committee

Headshot of Michael Gustafson


Michael Gustafson, PhD
May 2022 - Present

Mayo Clinic Arizona
Phoenix, USA

Headshot of Sandeep Soni


Sandeep Soni, MD
May 2020 - Present

CRISPR Therapeutics
San Francisco, USA


Maria Ester Bernardo, MD, PhD
San Rafaele Scientific Institute
Rome, Italy

Alexey Bersenev, MD, PhD
Yale University
New Haven, United States

Jaap Jan Boelens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, United States

Mitchell Cairo, MD
New York Medical College
New York, United States

Andrew Fesnak, MD
University of Pennsylvania
Philadelphia, United States

Patrick Hanley, PhD
Children's National Hospital
Washington, DC, United States

Margaret Lamb, MD
Nationwide Children's Hospital
Columbus, United States
ESP Leadership Development Program

Dean Lee, MD, PhD
Nationwide Children's Hospital
Columbus, United States

Bruce Levine, PhD
University of Pennsylvania
Philadelphia, United States

Shari Pilon-Thomas, PhD
Moffitt Cancer Center
Tampa, United States

Paula Rio, PhD
Madrid, Spain

Gaurav Sutrave, MBBS, FRACP, FRCPA
Westmead Institute for Medical Research
Westmead, Australia
ESP Leadership Development Program

Zulema Romero Garcia, PhD
University of California, Los Angeles
Los Angeles, United States